About:
RUBY-3 is being conducted to determine if a novel investigational drug, povetacicept, is safe and potentially beneficial for people with IgA nephropathy (IgAN). Povetacicept is designed to reduce the inflammation and harmful antibodies that damage the kidneys in patients with IgAN, reducing or possibly reversing kidney damage.
Eligibility
-
Be at least 18 years of age
-
Have IgAN that is confirmed by a biopsy
-
Currently have active IgAN despite receiving standard treatment(s)
-
Have lupus nephritis that is confirmed by a biopsy
-
Currently have active lupus nephritis despite receiving standard treatment(s)
-
Have primary membranous nephropathy that is confirmed by a biopsy
-
Currently have active membranous nephropathy despite receiving standard treatments
If you’re interested in participating in one of our Research Studies:
Call
303-232-3366
ext 2150, 2170 or 2190